Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Supreme flags record full-year financial performance

(Sharecast News) - Consumer goods specialist Supreme announced a record financial performance for the year ended 31 March in a trading update on Wednesday. The AIM-traded firm flagged organic revenue and profit growth across all of its divisions, nearly doubling its profitability year-on-year and ending the year debt-free.

It said it expected to report full-year revenue of £225m, up from £155.6m year-on-year, and Adjusted EBITDA of at least £38m, rising from £19.4m and aligning with current market expectations.

Supreme said its strategic investments in rechargeable pod system vaping devices, coupled with its diverse vape product mix, positioned it to adapt to shifts in the UK e-cigarette market.

Additionally, it said it remained committed to driving organic growth, strategic cross-selling, and exploring complementary acquisition opportunities to diversify and scale the business further.

The group's sports nutrition and wellness, lighting, and batteries divisions also demonstrated profitability and resilience.

Its board said it was confident in the group's future prospects.

The company's audited financial results for the period would be announced on 2 July.

At 1243 BST, shares in Supreme were up 3.33% at 125.55p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Sirius Real Estate ups dividend as profits jump 32%
(Sharecast News) - Profits at business and industrial parks developer Sirius Real Estate surged by nearly a third in the year ended 31 March, helping the company to increase dividends for the tenth straight year.
GSK to appeal Delaware ruling on jury trials in Zantac cancer cases
(Sharecast News) - Pharma giant GSK said it would be appealing against a US court decision allowing jury trials in cases brought by cancer sufferers claiming its heartburn drug caused their condition.
AstraZeneca's lung cancer treatment recommended for approval in EU
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.
China manufacturing PMI ticks up more than expected - Caixin
(Sharecast News) - Activity in China's manufacturing sector grew in May at the fastest rate in two years, according to data released on Monday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.